Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-86,283
-
Total reported value, excl. options
-
$0
-
Value change
-
-$425,556
-
Number of sells
-
-2
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2025
2 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 104,661,494 outstanding shares and own 0% of the company stock.
Largest 2 shareholders include DekaBank Deutsche Girozentrale (0 shares) and Global Retirement Partners, LLC (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.